manufacturing Archives | Page 4 of 4

Mustang Bio Establishes CAR T Cell Therapy Manufacturing Facility in Massachusetts

October 30, 2017 By Cade Hildreth, Founder & President Leave a Comment

Facility located in the UMass Medicine Science Park will support clinical development and commercialization of CAR T pipeline

Preparations underway for clinical production in 2018

NEW YORK, Oct. 30, 2017 — Mustang Bio, Inc. (“Mustang”) (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell (CAR T) technology, announced today that it has entered into a lease agreement with the UMass Medicine Science Park in Worcester, Massachusetts, for a manufacturing facility to support the clinical development and commercialization of the Company’s CAR T product candidates.

The facility is expected to be operational for the production of personalized CAR T therapies in 2018. Mustang anticipates initially building cell-processing capabilities to support its lead CAR T product candidates MB-101 in glioblastoma, and MB-102 in acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. [Read more…]

Evolution of the Cell Therapy CDMO Market

July 26, 2017 By Cade Hildreth, Founder & President Leave a Comment

Traditionally, the contract development and manufacturing organization (CDMO) market was for pharmaceutical services, including drug compound development and manufacturing. Over time, many pharmaceutical companies expanded into offering services for biopharmaceuticals and biologics as well, and a companies went as far as to specialize in cell therapy CDMO services. [Read more…]

Akron Biotech Partners in New Manufacturing USA Institute

January 25, 2017 By Cade Hildreth, Founder & President Leave a Comment

Akron Biotech is part of the Advanced Regenerative Manufacturing Institute (ARMI) consortium to develop next-generation manufacturing processes and technologies for cells, tissues and organs. The ARMI will receive nearly $300 million in public-private investment from leading manufacturers, universities, nonprofit organizations and the federal government to develop scalable manufacturing processes for engineered tissues and organs.

[Read more…]

Breaking: Cynata Reports Extremely Positive Interim Data for MSC Product, CYP-001, in Model of GvHD

April 7, 2016 By Cade Hildreth, Founder & President Leave a Comment

Australian stem cell company Cynata Therapeutics released news today than interim analysis clearly demonstrates efficacy of Cynata’s unique Cymerus™ mesenchymal stem cell (MSC) product, CYP-001, in a preclinical model of Graft-versus-Host disease (GvHD). This disease often follows a bone marrow transplant procedure and occurs when the immune cells in the donor material (the graft) attack the recipient’s tissues (the host) as “foreign”. Bone marrow transplants are used in the treatment of certain cancers, including leukaemia. [Read more…]

Cynata Introduces a Scalable Mesenchymal Stem Cell (MSC) Manufacturing Platform

October 19, 2015 By Cade Hildreth, Founder & President Leave a Comment

Cynata Therapeutics is a regenerative medicine company, listed on the Australian exchange with the ticker symbol CYP (ASX: CYP). The company recently broke onto the regenerative medicine scene by developing Cymerus™, a therapeutic stem cell platform technology that utilizes discoveries made at the University of Wisconsin-Madison (UWM).

UWM is a world-renowned leader in stem cell research that is best known for the work by Professor James Thomson’s research team, which succeeded in first isolating human embryonic stem cells (hESCs) in 1998 and successfully producing induced pluripotent stem cells (iPSCs) from human adult cells in 2007.

Cynata co-founder, Professor Igor Slukvin, was a member of the team that conducted UWM’s pioneering iPSC research. UWM is also infamous for its strong patent positions pertaining to the process of human embryonic stem cell (hESC) derivation. [Read more…]